Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718434 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HSD17B10KMT2AMEN1TLR4 | |
| SCHEMBL6098996 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HSD17B10KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4475842 | 0.84 | BRD4 (0.35) | ALDH1A1HSD17B10KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1303947 | 0.77 | ALDH1A1 (0.39) | ALDH1A1HSD17B10KMT2AMEN1TLR4 | |
| SCHEMBL6646578 | 0.77 | ACE (0.31) | KMT2A | |
| SCHEMBL3286134 | 0.76 | POLB (0.43) | ALDH1A1KMT2AMEN1TLR4SMN1; SMN2 | |
| SCHEMBL3367604 | 0.76 | ALDH1A1 (0.39) | ALDH1A1HSD17B10KMT2AMEN1TLR4 | |
| SCHEMBL22216375 | 0.74 | POLB (0.44) | ALDH1A1KMT2AMEN1TLR4SMN1; SMN2 | |
| SCHEMBL22216157 | 0.74 | POLB (0.41) | ALDH1A1KMT2AMEN1TLR4SMN1; SMN2 | |
| SCHEMBL23907332 | 0.74 | MAPT (0.51) | ALDH1A1HSD17B10KMT2AMEN1TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875626-B2 | 3,3,3-trifluoropropane-1-sulfonic acid 4-[1-(2-chlorophenyl)-3-methyl-4-oxo-5-piperidin-1-yl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine-2-yl]phenyl ester; treatment of obesity, psychiatric and neurological disorders | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| EP-1937679-B1 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-20080312269-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080262026-A1 | Therapeutic Agents 684 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-7071207-B2 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1432708-B1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORP (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262026-A1 | Therapeutic Agents 684 | GPR119, NLN, PYGB | ALDH1A1 618/4885HSD17B10 1050/4885KMT2A 2968/4885 |
| US-20080009513-A1 | Therapeutic agents | NLN, GPR119, FABP4 | ALDH1A1 403/4885HSD17B10 490/4885KMT2A 3490/4885 |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | GPR119, GIPR, PGC | ALDH1A1 3534/4885HSD17B10 2730/4885KMT2A 1681/4885 |
| US-20080312269-A1 | Therapeutic Agents | NLN, GRIN2C, GPR119 | ALDH1A1 612/4885HSD17B10 911/4885KMT2A 3667/4885 |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | GPR119, GIPR, PGC | ALDH1A1 2626/4885HSD17B10 1298/4885KMT2A 1796/4885 |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | CNR1, CNR2, GPR18 | ALDH1A1 4335/4885HSD17B10 3026/4885KMT2A 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.